首页> 外国专利> DICARBONIC ACID DERIVATIVES, METASTASIS INHIBITORS AND AGENTS INCREASING CHEMOTHERAPEUTIC ACTIVITY OF ANTI-TUMOR PREPARATIONS, METHOD FOR ENHANCING EFFICIENCY OF CYTOSTATICS AND METHOD FOR INHIBITING METASTASIS PROCESS

DICARBONIC ACID DERIVATIVES, METASTASIS INHIBITORS AND AGENTS INCREASING CHEMOTHERAPEUTIC ACTIVITY OF ANTI-TUMOR PREPARATIONS, METHOD FOR ENHANCING EFFICIENCY OF CYTOSTATICS AND METHOD FOR INHIBITING METASTASIS PROCESS

机译:双碳酸衍生物,转移抑制剂和增加抗肿瘤制剂化学治疗活性的药剂,增强细胞统计效率的方法和抑制转移过程的方法

摘要

The invention relates to dicarbonic acid derivatives and concerns dicarbonic acid monooxydamines and dioxydamides, which are physiologically active substances and can be used as low-toxic and non-toxic agents for enhancing the anti-tumor and anti-metastasis effects of known cytostatics (cyclophosphane and cisplatin) in cytostatic chemotherapy of tumors. The object of the present invention is to broaden the assortment of agents affecting a live organism in order to enhance anti-tumor and anti-metastasis effects of known cytostatics. Tiiis object is resolved by the properties of dicarbonic acid monooxydamines and dioxydamides. The essence of the invention consists in that dicarbonic acid derivatives, the formulas of which are presented in the specification, are proposed as agents for enhancing anti-tumor and anti-metastasis effects of cytostatics. The claimed compounds can be used in medical practice as low-toxic agents for enhancing anti-tumor and anti-metastasis effects of known cytostatics with a simultaneous 4-fold reduction of the therapeutic dose of cytostatics. The use of the proposed compounds in a combination with cisplatin at the minimum doses makes it possible to completely inhibit the metastasis process in experimental B-16 melanoma. Furthermore, the use of the proposed compounds at the mininium doses in a combination with the minimum doses of cytostatics (when neither of the preparations alone exhibitsefficacy) makes it possible to obtain a high therapeutic effect in treating leukemias (survival of animals with P-388 leukemia in the test group is 100%).
机译:本发明涉及二碳酸衍生物,并涉及二碳酸单氧胺和二氧化二胺,它们是生理活性物质,可以用作低毒和无毒剂,以增强已知细胞抑制剂(环磷酰胺和环磷酰胺)的抗肿瘤和抗转移作用。顺铂)用于肿瘤细胞抑制化疗。本发明的目的是拓宽影响活生物体的试剂的种类,以增强已知细胞抑制剂的抗肿瘤和抗转移作用。本发明的目的通过二碳酸单氧胺和二氧damides的性质解决。本发明的实质在于提出了在说明书中给出其式的二碳酸衍生物作为增强细胞抑制剂的抗肿瘤和抗转移作用的试剂。所要求保护的化合物可以在医学实践中用作低毒剂,以增强已知细胞抑制剂的抗肿瘤和抗转移作用,同时将细胞抑制剂的治疗剂量降低4倍。所建议的化合物与顺铂以最小剂量组合使用可以完全抑制实验性B-16黑色素瘤的转移过程。此外,将建议的化合物以最小剂量与最小剂量的细胞抑制剂(当两种制剂均未显示出药效)结合使用时,可以在白血病(P-388动物的生存)中获得很高的治疗效果。测试组中的白血病为100%)。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号